Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mosquito-born virus disease characterized by a clinical course that may be asymptomatic or mild with fever, conjunctivitis, muscle and joint pain, headache, exanthema, but may also be associated with severe neurological (meningitis, meningoencephalitis and myelitis) and auto-immune (Guillain-Barre syndrome) complications, as well as a potential increase of birth defects (microcephaly) if the infection occurs during pregnancy.
Biomarker and diagnostic research for Zika virus infectious disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
7 clinical trials registered, 2 recruiting. Interventions under study include other interventions. Pipeline includes 2 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT01386424](https://clinicaltrials.gov/study/NCT01386424) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:56 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Zika virus infectious disease
— |
National Institute of Allergy and Infectious Diseases (NIAID) |
RECRUITING |
[NCT06859619](https://clinicaltrials.gov/study/NCT06859619) | Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases | NA | University Hospital, Montpellier | NOT_YET_RECRUITING |
[NCT04619823](https://clinicaltrials.gov/study/NCT04619823) | Virological and Immunological Determinants of Arbovirus Infection in New Caledonia | NA | Institut Pasteur | UNKNOWN |
[NCT07358910](https://clinicaltrials.gov/study/NCT07358910) | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective | — | Institut Pasteur du Cambodge | RECRUITING |
[NCT04398901](https://clinicaltrials.gov/study/NCT04398901) | Neurodevelopmental Outcomes in ZIKV-Exposed Children | — | Children's National Research Institute | UNKNOWN |
324 publications have been identified in PubMed for Zika virus infectious disease. Kisho has analyzed 127 by research type. Research spans Review / Meta-Analysis (43%), Basic Science / Preclinical (30%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 54 | 43% |
Laboratory research | 38 | 30% |
Disease patterns and progression | 20 | 16% |
New treatment approaches | 9 | 7% |
Patient case studies | 2 | 2% |
Clinical study results | 2 | 2% |
Other research | 1 | 1% |
Testing and diagnosis research | 1 | 1% |
Kumar R (2026). [PMID: 41297861](https://pubmed.ncbi.nlm.nih.gov/41297861/). *Int J Pharm*. [Review / Meta-Analysis]
Li Q (2026). [PMID: 42161262](https://pubmed.ncbi.nlm.nih.gov/42161262/). *Cell Host Microbe*. [Gene Therapy / Novel Therapeutics]
McCluskey JM (2026). [PMID: 38861626](https://pubmed.ncbi.nlm.nih.gov/38861626/). *Unknown Journal*. [Epidemiology / Natural History]
Ju X (2026). [PMID: 41779781](https://pubmed.ncbi.nlm.nih.gov/41779781/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
Justiz Vaillant AA (2026). [PMID: 30860698](https://pubmed.ncbi.nlm.nih.gov/30860698/). *Unknown Journal*. [Epidemiology / Natural History]
Ranzani OT (2026). [PMID: 40845862](https://pubmed.ncbi.nlm.nih.gov/40845862/). *Lancet Infect Dis*. [Clinical Trial Publication]
Micheletti CA (2026). [PMID: 41314423](https://pubmed.ncbi.nlm.nih.gov/41314423/). *Am J Med Sci*. [Review / Meta-Analysis]
McCain K (2026). [PMID: 41800449](https://pubmed.ncbi.nlm.nih.gov/41800449/). *Nat Health*. [Review / Meta-Analysis]
Yuji Sasazaki F (2026). [PMID: 41772670](https://pubmed.ncbi.nlm.nih.gov/41772670/). *Virology journal*. [Review / Meta-Analysis]
Leite-Aguiar R (2026). [PMID: 40364625](https://pubmed.ncbi.nlm.nih.gov/40364625/). *Neural Regen Res*. [Basic Science / Preclinical]
AI-curated news mentioning Zika virus infectious disease
Updated Feb 6, 2026
The CDC identifies various countries and territories at risk for Zika virus transmission, highlighting the need for ongoing surveillance and public health measures. This information is crucial for travelers and health officials to mitigate potential outbreaks.
The CDC held a teleconference discussing the impact of Zika virus on babies in US territories. This session aimed to raise awareness and share insights on the ongoing challenges faced by affected families.
A recent CDC report highlights that approximately 14% of babies born to mothers infected with Zika virus during pregnancy exhibit health problems potentially linked to the virus. Many of these issues may not have been evident at birth, underscoring the need for ongoing monitoring and support.